Journal of Korean Breast Cancer Society最新文献

{"title":"Micropapillary Carcinoma of Breast","authors":"Jonghan Yu, S. Kim, W. Han, Sung-Won Kim, I. Park, Y. Youn, S. Oh, K. Choe, D. Noh","doi":"10.4048/JKBCS.2004.7.2.132","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.2.132","url":null,"abstract":"Purpose: Micropapillary carcinoma in breast cancer was first described by Petersen in 1993, after which other reports from all over the world described their characteristics. In Korea, this type of carcinoma was first described in 1996. The purpose of our study was to find the clinicopathological characteristics of micropapillary carcinomas from our experiences and to compare the results with those of other studies. Methods: We analyzed 19 patients, from Dec. 1999 to Dec. 2002, diagnosed with micropapillary carcinomas from postoperative pathological reports retrospectively, compared with 939 patients diagnosed with infiltrating duct carcinoma in the same period. Results: The mean age and tumor size were 46.8 years (range 32∼73) and 3.75cm (range 0.5∼10.0), respectively. Micropapillary carcinoma showed the larger size (P=0.032) and more frequent rates of lymphovascular invasion (P= 0.007) and metastasis to axillary lymph nodes (P=0.003) than infiltrating duct carcinoma. But, in the T stage-matched analysis, the rates of axillary lymph node metastasis in micropapillary carcinoma and infiltrating duct carcinoma showed no significant differences (T1, T2, T3 : P=0.072, P= 0.080, P=0.575 ). Only in T2 stage, rates of lymphovascular invasion showed more frequent significantly in micropapillary carcinoma (P=0.012). Age, nuclear and histological grades showed no significant differences. The positive expressions of estrogen and progesterone receptors were more frequent in micropapillary carcinoma compared with infiltrating duct carcinoma, while the expressions of the C-erb-B2, p53, Ki-67 and bcl-2 showed no significant differences. Conclusion: The micropapillary carcinomas showed more frequent lymphovascular invasion and positive expressions of the estrogen and progesterone receptors in their immunohistochemistry. (Journal of Korean Breast Cancer Society 2004;7:132-135)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124137761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Different Expression of p27kip1 and p57kip2 by Genistein Treatment in MDA-MB-231 Human Breast Cancer Cells","authors":"D. Yoon, K. Song, Sung Tae Kim","doi":"10.4048/JKBCS.2004.7.2.98","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.2.98","url":null,"abstract":"유방암은 우리나라 부인암 중에서 첫 번째로 발생빈도 가 높은 암으로 점차 그 발생 빈도가 증가 추세를 보이고 있어 유방암의 조기발견과 예방 및 치료에 많은 연구가 필요하다. 현재까지 다양한 종양 유전자, 조절인자, 종양 억제 유전자들이 종양의 형성에 영향을 끼치며, 종양세포 의 자연사멸과 증식 간의 불균형이 종양 크기의 증가와 관련이 있다는 연구 결과가 많이 보고되고 있다.(1) 다른 암과 마찬가지로 유방암 역시 여러 가지 유전자의 변이 및 발현 양상의 변화에 의해 발생되는 것으로 알려져 있 고, 지금도 많은 관련 유전자들이 보고되고 있다. 세포의 분열은 세포 내, 외부로부터 전달된 다양하고 복잡한 신호들에 의해 조절되는데, 이 신호들은 결국 cyclindependent kinases (Cdks)의 활성을 조절하는 쪽으로 귀결 된다. 세포분열의 정확한 조절은 세포의 분화에도 중요하 다. 대부분의 세포는 분화하기 위해서 세포주기의 G1기에 서 분열을 멈춘다. 그래서 G1기에서 S기로 넘어가는 것을 특이적으로 억제하는 인자에 대한 연구가 근래의 몇 년간 이루어져 왔다. G1기에서 S기로 들어가려면 Cdk2-cyclin E, Cdk4/6-cyclin D의 복합체 형성이 필요하다. 이 복합체 의 활성을 CdK inhibitors (CKIs)가 결합하여 억제하게 된 다. CKIs에는 그들의 구조적인 특성과 Cdk의 억제 방법, 기질 특이성 등에 따라 CIP/KIP와 INK4 family로 나눈다. CIP/KIP family에는 p21, p27, p57이 속하는데, Cdk4/6-cyclin D, Cdk2-cyclin E 복합체 모두를 억제한다. 그러나 INK4 family는 Cdk4/6-cyclin D 복합체만 억제할 수 있 다.(2) 분화하는 많은 조직에서 CIP/KIP 단백질들이 많이 발현되는 것으로 보아, 이 단백질들이 세포의 분열을 멈 춤으로써 분화를 시작하게 하는 것으로 추측하고 있다.(3) 초파리의 배아 발달 과정에서 cyclin E의 억제와 Cdk inhibitor의 증가가 세포 주기의 정지를 야기시키고 정상적 인 배아 발달에 영향을 준다는 것이 밝혀져서 G1-phase regulation에 CIP/KIP family의 역할에 많은 관심이 모아지 고 있다. 그중 p27 kip1 은 TGF-β, rapamycin, contact inhibiMDA-MB-231 유방암 세포에서 Genistein 처리에 의한 p27과 p57의 발현 변화","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131159324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of bcl-2 and Apoptosis and Its Relationship to Clinicopathological Prognostic Factors in Breast Cancer - A Study with Long Term Follow-up","authors":"Ju Han Lee, E. Lee, C. Kim","doi":"10.4048/JKBCS.2004.7.2.92","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.2.92","url":null,"abstract":"종양의 발생과 진행에서 세포자멸사(apoptosis)와의 관 계에 대한 연구가 활발히 이루어지고 있다. 세포자멸사란 생리적으로 발생하는 예정된 세포의 죽음으로 원치 않는 세포가 제거되는 자연 과정을 말한다.(1) 세포자멸사는 세 포자멸사를 억제하는 유전자와 유도하는 유전자들에 의 해 조절된다. 세포자멸사의 발생에서 세포를 보호하며 세 포 생존을 도모하는 bcl-2유전자는 원형 종양 유전자(protooncogene)의 일종으로 B세포 백혈병과 여포성 림프종 (follicular lymphoma)에서 종종 발견되는 t (14:18) 염색체 이 상에 대한 연구에서 염색체 18q21에 위치하고 있다는 것 이 확인되었다.(2-4) 그 산물인 bcl-2단백질은 내형질세막 (endoplasmic reticulum), 미토콘드리아와 핵막 등에 존재하 면서 사이토카인과 함께 세포자멸사를 억제하여 정상 세 포의 교체에 중요한 역할을 한다.(5,6) 세포자멸사는 종양 의 발생에 있어서 중요한 역할을 하게 되는데, 세포자멸 사를 조절하는 종양 유전자들의 변화에 의해 세포자멸사 가 억제됨으로써 클론의 팽창(clonal expansion)이 일어나 종양이 발생하고, 이에 관련된 중요한 유전자로는 p53, bcl2, c-myc 등이 있다.(7,8) 이러한 유전자들 중 bcl-2 유전자 는 세포자멸사를 억제함으로써 세포의 수명을 연장시켜 종양 억제 유전자 혹은 세포증식과 연관된 유전자들의 유 전적 결함의 기회를 증가하게 하여 암을 유발한다.(9,10) 정상적으로 bcl-2 유전자는 B 림프구 이외에도 호르몬에 의해 성장과 위축이 조절 받는 장기인 유방이나 stem cell 을 가지고 있는 장과 피부, 그리고 완전히 분화되어 오랜 수명을 가지는 신경세포 등에서 발견되고, 유방에서는 태 아와 성인의 정상적인 유방조직에서 발현된다.(11,12) 유 장기 추적 관찰을 통한 유방암에서 세포자멸사(apoptosis)와 bcl-2 단백질 발현과 예후인자와의 상관관계","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121272025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Metastatic Thyroid-Papillary Carcinoma to the Breast","authors":"Yong Hwan Park, T. Heo, Ki Hong Kim, Young-Jin Park, Myung-Soo Lee, Chul-Nam Kim, M. Kim, S. Chang","doi":"10.4048/JKBCS.2004.7.1.55","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.1.55","url":null,"abstract":"유방 이외의 조직에서 발생한 악성 종양이 유방으로 전 이되는 경우는 매우 드문 것으로 알려져 있다. 그 발생빈 도는 저자들마다 다양한 차이가 있으며, 전체 유방암에서 차지하는 비율은 0.4∼1% 정도로 보고되고 있다.(1-3) 유 방으로 전이를 일으키는 원발성 종양의 종류를 Donmanski (3)는 악성림프종, 혈액암, 기관지 암종 등이며, Toombs와 Kalisher (2)는 악성 흑색종, 림프종/백혈병 및 폐와 위에서 전이된 암종이라고 보고하였다. 한편 갑상샘 유두암종의 경우 전이는 림프계을 통하여 주로 폐나 뼈, 주위 조직으 로 전이되는 것으로 알려져 있으며,(4,5) 유방으로 전이된 경우는 극히 드물고 국내에서는 아직 보고된 바가 없다. 저자들은 양측 유방의 종괴를 주소로 내원하여 절제술을 시행하여, 병리조직 검사상 양측 유방 종괴 모두 갑상샘 유두암종이 전이된 것으로 확인된 1예를 임상 경험하였기 에 문헌고찰과 함께 보고하는 바이다.","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127586670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of Hypoechoic Mass by Fine-Needle Aspiration","authors":"Dong Seok Lee, Jong Ki Lee, Ji Whoa Kim","doi":"10.4048/JKBCS.2004.7.1.37","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.1.37","url":null,"abstract":"유선조직이 치밀한 한국 여성에서는 유방에 대한 검사로 초음파검사가 많이 시행된다. 유방 초음파검사를 실시하면 유방암을 위시하여 다양한 병변들이 우연히 발견되는 경우 가 많이 있다. 이러한 병변이 ‘양성으로 여겨지는(probably benign) 병변'인 경우에는 정기적인 추적검사를 받을 것을 권한다. 그러나 환자들은 추적검사에 대해 심한 불안감을 가지게 되어 다른 의사를 찾아 2차 의견을 구하거나 값비싼 맘모톰 시술을 통해 병변을 제거하려는 경향이 있다. 그런 데 세침흡인으로 간단히 제거할 수 있는 유방 낭종도 초음 파 검사상 저에코의 종괴로 발현되고(Fig. 1) 이것이 양성종 양으로 오인되어 환자에게 불필요한 추적검사나 조직생검 의 부담을 갖게 하는 경우를 우리는 흔히 경험하게 된다. 본 연구에서 저자들은 초음파검사로 발견되는 1 cm 미만의 저에코성 종괴 중 세침흡인으로 없앨 수 있는 비전형적 유 방 낭종이 얼마나 되는지를 알아보고, 세침 흡인 전에 미리 비전형적 유방 낭종임을 예측할 수 있는 임상적, 초음파 영 상적 지표들이 어떤 것이 있는지를 살펴보고자 하였다. 또 한 1 cm 미만의 저에코성 종괴가 발견되었을 때 세침흡인 을 일률적으로 시행하는 것이 타당한지에 대해서도 알아보 고자 하였다.","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"156 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122614317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy of Quantitative Scintimammography Using Tc-99m Tetrofosmin according to ROC Curve Analysis for Breast Cancer","authors":"Sang-Heum Park, H. Park, S. Han, Young Don Lee, M. Jung, Tae Hoon Lee, J. Oh, Jung Nam Lee, W. Lee, Y. Park, S. Min, J. Baek, J. Kim, K. Hwang","doi":"10.4048/JKBCS.2004.7.1.49","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.1.49","url":null,"abstract":"Purpose: Tc-99m Tetrofosmin is a new alternative to Tc99m MIBI for nuclear breast imaging. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the feasibility of Tc-99m Tetrofosmin quantitative scintimammography (SMM) (qSMM) and to compare with previously reported Tc-99m MIBI qSMM data [J Kor Surg 1999;57(5):638-644)]. Methods: Prone anterior, lateral planar and supine SPECT images were taken from 135 cases in 131 female patients (mean ages=44 yr) with breast mass (size≥0.2 cm) after 30mCi intravenous injection of Tc-99m Tetrofosmin. 70 malignant and 65 benign lesions were histologically proven. Three regions of interest (ROIs) were drawn over designated areas: the Lesion (L), the Normal breast opposite the lesion (NL) and the right Chest wall (CW). L/NL and L/CW ratios on both the SPECT and the planar images were analyzed. Results: ROC curve analysis revealed that the planar L/NL ratio and the SPECT L/NL and L/CW ratios had higher diagnostic accuracy for detecting breast cancer than the planar L/CW ratio did (P<0.05). The qSMM (mean), which is an arithmetic mean of the planar L/NL ratio, the SPECT L/NL ratio and the SPECT L/CW ratio, the sensitivity, the specificity, accuracy and area under curve (AUC) were 82.9%, 81.5%, 82.2% and 0.879 respectively. Presence of axillary lymph node metastasis showed a slightly higher qSMM (mean) value (2.79 {n=23} vs 2.75 {n=27} P=0.06). These are comparable with previously reported Tc-99m MIBI qSMM data of 84.4%, 76.6%, 81.0% and 0.847 respectively, and the presence of axillary lymph node metastasis showed a higher qSMM(mean) value (4.09 {n=17} vs 3.09 {n=28}, P=0.06) [J Kor Surg 1999; 57(5):638-644)]. Conclusion: Tc-99m Tetrofosmin qSMM (mean) is a useful and objective method for differentiating malignant from benign breast lesion and has the comparable diagnostic accuracies of Tc-99m MIBI qSMM. (Journal of Korean Breast Cancer Society 2004;7:49-54)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130676738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Breast Masses Detected only by Ultrasonography","authors":"W. Sun, Y. Song, H. Yun, D. Ryu","doi":"10.4048/JKBCS.2004.7.1.43","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.1.43","url":null,"abstract":"Purpose: Whether they are mammographically visible or not, breast ultrasonography is widely used for differential diagnosis of palpable breast masses. The aim of this study is to evaluate the usefulness of cytological examinations and ultrasonographical follow-ups in the management of non-palpable, mammographically non-visible breast masses incidentally detected only by ultrasonography screening. Methods: One hundred forty-six lesions of non-palpable and mammographically non-visible, but ultrasonographically detected solid masses (sonic masses) from 120 female patients were examined at the Breast Clinic, Chungbuk National University Hospital from January, 2000, to February, 2003. We performed ultrasonogram-guided percutaneous fine-needle aspiration biopsy in all sonic masses and proceeded all sonic masses by sequential ultrasonography at 3-, 6and 12-month intervals if there was no suspicion of malignancy. Results: One hundred thirty-eight lesions (94.5%) were ultrasonographically diagnosed as benign and eight lesions (5.5%) as malignant. Eight ultrasonographically malignant lesions were all proved to be benign by cytological examinations or ultrasonogram-guided needle localization biopsies and not palpable during the follow-up period. Cytological interpretations revealed 127 lesions (87.0%) as benign, 5 lesions (3.4%) as atypical epithelial cells and 14 lesions (9.6%) as nondiagnostic. Five atypical epithelial lesions were found benign through ultrasonogram-guided needle localization biopsies or core needle biopsies in the final diagnosis. The ultrasonography was used for follow-up in all lesions. There was no evidence of malignancy in any lesion during the follow-up. Conclusion: In our study, there was no evidence of malignancy in breast sonic masses during the follow-up period. Our data showed that sequential ultrasonographical follow-up is sufficient for ultrasonographically benign sonic masses. (Journal of Korean Breast Cancer Society 2004;7:43-48)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"104 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131769988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Stem Cells","authors":"Dongho Choi, R. Clarke, M. H. Lee","doi":"10.4048/JKBCS.2004.7.1.1","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.1.1","url":null,"abstract":"2001년 보건복지부 암 등록 보고에 의하면 우리 나라 여 성에서 발생하는 암 중에서 유방암이 가장 많이 발생하 며, 그 발생빈도가 점차 증가하는 것으로 나타나고 있 다.(1) 유방암에 있어서 치료는 조기에 유방암을 발견하여 적극적인 치료로 완치하는 것을 목적으로 하고 있다. 하 지만 이러한 노력에도 불구하고 유방암 수술 후나 항암화 학요법 및 호르몬치료 후에 재발되는 환자들에 대한 치료 법은 부족한 상태이다. 최근에 유방암의 치료적인 면에서 각 장기에 있는 줄기세포가 유방암에도 있고 이러한 유방 줄기세포가 암세포와 여러 면에서 동일한 특징을 가지고 있어서 유방암의 발생에 밀접한 관계가 있을 것이라는 보 고가 있고,(2) 유방암수술 후에 조직 재건 시에도 유방줄 기세포를 이용한 조직공학의 개념이 도입되어(3) 유방줄 기세포의 존재 여부, 특성 등을 연구하는 것이 유방암의 치료에서 중요해졌다.","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"308 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125767583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Characterization of CpG Methylation of ERα and ERβ Gene in the Breast Cancer","authors":"S. Kim, Tae Won Kim, S. Y. Lee, Sang Jae Park, E. Lee, H. Kang","doi":"10.4048/JKBCS.2004.7.1.8","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.1.8","url":null,"abstract":"Purpose: Aberrant methylation of promoter cytosine guanine dinucleotide (CpG) islands is known to be responsible for the alteration and silencing of cancer genes. The data presented here show that most methylations of Estrogen Receptorα (ERα) and ERβ are found at or near the transcriptional factor binding sites in the breast cancer tissues. Methods: Fifty archival breast cancer tissues and twentyfive normal tissues were selected and the status of the methylation and the transcription were investigated by bisulfite genomic sequencing and reverse transcription (RT) PCR. Results: Consequently, the hypermethylation of ERα and ERβ genes was found in 66.0% and 50.0% of 50 breast cancers, respectively. In particular, the methylation sites were frequently located near the CCAAT box (-363 and -375) for the ERα gene, and at or adjacent to binding sites of GATA (-217, -302) and Sp1 (+224, +227, +160) for the ERβ gene. The methylations at or near the binding sites were observed in most of the methylated cancers (ERα 87.9%, and ERβ 84.0%). The methylated cases were negatively correlated with the expression of ERα and ERβ RNA (P<0.01). In particular, tumors with CpG methylation of ERα and ERβ at or near the binding sites did not express mRNA, whereas those CpG methylation outside the sites showed moderate expression. Four tumors with methylated ERα genes at sites unrelated to the binding sites showed higher levels of protein expression than those with methylation at or near the sites (P=0.01). Conclusion: Although the number of samples was relatively small, our results suggest that DNA methylation in ERα and ERβ appears to take significant effect on transcriptional silencing and is most often present in the CpG sites at or near the putative transcriptional factor binding sites. We believe this finding offers a clue to the initiation or spread pattern of CpG methylation in human breast cancer. (Journal of Korean Breast Cancer Society 2004;7:8-16)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133264774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Single Institute's Experience of Standardization for the HER2 Status by Fluorescence in situ Hybridization and Immunohistochemistry on a Primary Breast Cancer Tissue Microarray","authors":"Kyeongmee Park, Sehwan Han","doi":"10.4048/JKBCS.2004.7.1.27","DOIUrl":"https://doi.org/10.4048/JKBCS.2004.7.1.27","url":null,"abstract":"Purpose: Most tests developed for the determination of the HER2 status still require validation, although identification of the HER2 status is important for predicting the response to specific systemic therapy in breast cancer. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were performed for the HER2 expression on the tissue microarray (TMA) from primary breast cancers to validate the feasibility of IHC for HER2 assay. Methods: A TMA was constructed from 134∼231 primary breast cancers. FISH and IHC were repeated more than twice, and the results were analyzed. Three kinds of primary antibody for IHC were used and compared. Results: The HER2 was amplified by FISH in 24∼28% of breast cancer with a concordance between multiple assays of 92∼100% (kappa=0.994-0.965), while the HER2 was overexpressed in 21∼27% by IHC. The HER2 was amplified in 70∼100% of the IHC 3+ cases, but was observed in only 45∼78% and 5∼12% of the IHC 2+ and IHC 0∼1+ cases, respectively. The results from the IHC, using 3 different primary antibodies to HER2, were in good agreement each other at 88∼92% (kappa=0.902-0.799). Conclusion: The results of the FISH appeared to be more reproducible than those of the IHC in the current study. The results of the IHC were not different from each other according to primary antibody used. However, a considerable proportions of the IHC positive cases were not confirmed by the FISH. This report indicates a need to improve the laboratory quality control measures when using the IHC for the HER2 assay, including the periodic testing for the concordance with FISH. (Journal of Korean Breast Cancer Society 2004;7:27-31)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125088258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}